Plus Therapeutics (PSTV) to Release Quarterly Earnings on Thursday

Plus Therapeutics (NASDAQ:PSTV) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $1.2280 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Plus Therapeutics Stock Performance

Shares of PSTV opened at $0.24 on Thursday. The stock has a fifty day moving average of $0.29 and a two-hundred day moving average of $0.48. The company has a market capitalization of $40.49 million, a PE ratio of -0.19 and a beta of 0.79. Plus Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $2.08.

Hedge Funds Weigh In On Plus Therapeutics

A number of hedge funds have recently made changes to their positions in PSTV. Geode Capital Management LLC lifted its holdings in shares of Plus Therapeutics by 72.5% during the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after acquiring an additional 589,544 shares in the last quarter. Jane Street Group LLC acquired a new stake in Plus Therapeutics in the 4th quarter valued at $525,000. Virtu Financial LLC purchased a new position in Plus Therapeutics in the fourth quarter valued at about $254,000. State Street Corp raised its position in Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Plus Therapeutics during the fourth quarter worth about $127,000. Hedge funds and other institutional investors own 3.28% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on PSTV. HC Wainwright reaffirmed a “buy” rating and issued a $1.00 price objective (down from $2.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Lake Street Capital began coverage on Plus Therapeutics in a research report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 target price on the stock. Ascendiant Capital Markets decreased their price target on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Finally, D. Boral Capital dropped their price objective on shares of Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.80.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.